bevirimat

an HIV inhibitor; disrupts late step in processing HIV Major Core Protein p24, preventing the capsid precursor p25 from being converted to mature capsid p24

Also Known As:

3-O-(3',3'-dimethylsuccinyl)betulinic acid; MPC-4326; MPC4326; PA 457; PA-103001; PA-103001-01; PA-457; PA-457 DI-NMG; PA-457N; PA103001; PA103001-01; PA103001-04; PA457; bevirimat dimeglumine; bevirimat dimeglumine salt; bis(1-deoxy-1-(methylamino)-D-glucitol) 3beta-(3-carboxylato-3-methylbutanoyloxy)lup-20(29)-en-28-oate; dsb-2nmg; lup-20(29)-en-28-oic acid, 3-(3-carboxy-3-methyl-1-oxobutoxy)-, (3beta)-, compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:2)

Networked: 13 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Terpenes: 1461
    - Triterpenes: 2493
      - Pentacyclic Triterpenes: 108
        bevirimat: 13
- Carboxylic Acids: 973
  - Acyclic Acids
    - Dicarboxylic Acids: 108
      - Succinates: 13
        bevirimat: 13

Experts

1.	Martin, David E: 5 articles (10/2008 - 09/2007)
2.	Doto, Judy: 3 articles (10/2008 - 09/2007)
3.	Salzwedel, Karl: 3 articles (01/2008 - 11/2006)
4.	Lee, Kuo-Hsiung: 2 articles (09/2010 - 03/2010)
5.	Galbraith, Hal: 2 articles (10/2008 - 09/2007)
6.	Allaway, Graham P: 2 articles (01/2008 - 10/2007)
7.	Wilton, John: 2 articles (10/2007 - 09/2007)
8.	Alcamí, José: 1 article (01/2018)
9.	Bazzocchi, Isabel L: 1 article (01/2018)
10.	Bedoya, Luis M: 1 article (01/2018)

Related Diseases

1.	HIV Infections (HIV Infection) 05/01/2010 - "[Prediction of the efficacy of bevirimat used for the treatment of HIV infection in Russia]." 08/01/2006 - "Panacos Pharmaceuticals Inc is developing the HIV Gag protein and viral maturation inhibitor bevirimat for the potential oral treatment of HIV infection. " 09/01/2007 - "Bevirimat (BVM; formerly known as PA-457) is a novel inhibitor of human immunodeficiency virus (HIV) maturation that is being developed for the treatment of HIV infection. " 10/01/2008 - "Bevirimat is the first drug in the class of maturation inhibitors, which treat HIV infection by disrupting the activity of HIV protease enzyme with a mechanism of action distinct from that of conventional protease inhibitors. "
2.	Infections 10/01/2008 - "Bevirimat, an inhibitor of HIV-1 maturation, is currently in clinical development for the treatment of HIV-1 infection. " 01/01/2008 - "Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection." 11/01/2006 - "These findings have implications for the ongoing development of PA-457 to treat HIV-1 infection in vivo." 01/01/2018 - "The three LPTs inhibited HIV-1 infection of human primary lymphocytes and infections with protease inhibitors and bevirimat resistant HIV-1 variants with similar values of IC50. " 10/01/2007 - "HIV RNA was modeled as being produced in infected CD4 cells, with bevirimat inhibiting infection of new CD4 cells thru a Hill-type function (r(2), 0.87). "
3.	Acquired Immunodeficiency Syndrome (AIDS) 09/01/2010 - "These compounds were equipotent or more potent than 3-O-(3',3'-dimethylsuccinyl)betulinic acid (2), which is currently in Phase IIb anti-AIDS clinical trial." 03/26/2010 - "Current clinical trial agents discovered by the Natural Products Research Laboratories, University of North Carolina, include bevirimat (dimethyl succinyl betulinic acid), which is now in phase IIb trials for treating AIDS. "
4.	Respiratory Tract Infections (Respiratory Tract Infection) 10/01/2008 - "In addition, 17 subjects (35.4%) experienced treatment-emergent adverse events including: ocular icterus, 5; headache, 5; unconjugated blood bilirubin increases, 4; diarrhea, 3; upper respiratory tract infection, 3; and yellow skin, 3. In this study, there were no significant differences in PK properties in atazanavir or bevirimat administered as monotherapy or in combination in this small, select group of healthy volunteers. "
5.	Jaundice (Icterus) 10/01/2008 - "In addition, 17 subjects (35.4%) experienced treatment-emergent adverse events including: ocular icterus, 5; headache, 5; unconjugated blood bilirubin increases, 4; diarrhea, 3; upper respiratory tract infection, 3; and yellow skin, 3. In this study, there were no significant differences in PK properties in atazanavir or bevirimat administered as monotherapy or in combination in this small, select group of healthy volunteers. "

Related Drugs and Biologics

1.	bevirimat
2.	Atazanavir Sulfate (Reyataz)
3.	Bilirubin
4.	Betulinic Acid
5.	Simvastatin (Zocor)
6.	Paclitaxel (Taxol)
7.	Vaccines
8.	Sodium
9.	Protease Inhibitors (Protease Inhibitor)
10.	Aminolevulinic Acid (Levulan)

Related Therapies and Procedures

1.	Stents